ClinicalTrials.Veeva

Menu
C

Center for Clinical Studies | Clear Lake-Webster, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

JNJ-77242113
Apremilast
LY3454738
Ruxolitinib

Parent organization

This site is a part of Center for Clinical Studies

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 10 total trials

A Study of Barzolvolimab in Patients With Prurigo Nodularis

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.

Enrolling
Prurigo Nodularis
Other: Matching Placebo
Biological: barzolvolimab

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo an...

Enrolling
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/o...

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: JNJ-77242113

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (A...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: LY3454738

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Enrolling
Prurigo
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Lilly logo
Amgen logo
Celldex Therapeutics logo
Incyte logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems